A Phase 3 interventional study of Icatibant in Hereditary Angioedema, sponsored by Shire. Completed at 26 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-11.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing icatibant in Angioedemas, Hereditary — none open to participants now, none under way, none of them phase 3. icatibant · Angioedemas, Hereditary.
Among the 10 studies testing icatibant in Angioedemas, Hereditary, this one has the largest enrollment, is one of 2 that started in 2009, is one of 7 in phase 3, and was the 4th registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →None of the 10 studies testing icatibant in Angioedemas, Hereditary is open now. The open studies under Angioedemas, Hereditary, anywhere →
icatibant: first FDA approval 2011 (FIRAZYR), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2009.
This study's enrollment of 151 is above the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 26 across the 10 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 4 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
58 studies in Angioedemas, Hereditary by Takeda: 3 open now, 4 under way, none of them phase 3. Of 52 finished, 33 (63%) have results posted.
Among the 58 studies in Angioedemas, Hereditary by Takeda, this one is the 3rd largest by enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2009, is one of 23 in phase 3, and was the 12th registered.
Takeda’s Angioedemas, Hereditary studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing icatibant in Angioedemas, Hereditary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 58 in Angioedemas, Hereditary:
This tab as a report to print or save as PDF → With an account.
This study is being conducted to explore the clinical safety, local tolerability, convenience and effectiveness of self-treatment of hereditary angioedema (HAE) attacks with subcutaneous injections of icatibant.
This Phase IIIb study was multi-center and open-label with a single dose level. Subjects with a documented diagnosis of HAE Type I or II were eligible to participate in this trial. Eligible subjects included those who had received treatment for HAE with icatibant in previous clinical trials, or subjects who had been previously treated with the marketed product Firazyr® and subjects who were naïve to icatibant treatment.
All subjects were trained on the method of self-administration at their enrollment visit (Visit 1).For the training sessions, a syringe pre-filled with 3 mL placebo solution was used in place of icatibant. Comprehensive educational material and instructions including pictograms were developed for the subjects to illustrate the method of self-administration and use of the Patient Diary. The training material provided additional information on how to self-diagnose an HAE attack and how to decide on the necessity to treat.In addition, instructions were provided on what to do in case of a laryngeal attack.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Each patient must meet the following criteria to be enrolled in this study.
Documented diagnosis of HAE Type I or II based on ALL of the following criteria:
Exclusion Criteria:
Patients who meet any of the following criteria will be excluded from the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single subcutaneous injection of icatibant, 30 mg
Drug: Icatibant
Single subcutaneous injection of icatibant, 30 mg
Drug: Icatibant
Single subcutaneous injection of icatibant, 30 mg
Also known as: Brand name, Firazyr®
Number of Participants With Adverse Events in Self-treatment of Acute HAE Attacks With s.c. Injections of Icatibant
Clinical safety of self-treatment of acute HAE attacks with s.c. injections of icatibant was assessed by calculating the number of AEs occurred during the study. Only those adverse events occurring up to the earlier of 7 days from the start of the naive phase, study discontinuation and start of the self-administration phase are assessed. The Local Tolerability Assessment tool was used. Subjects and Investigators graded erythema/reddening, swelling, burning, pruritus/itching, warm sensation, and skin pain on a 0 to 3 severity scale.
Time frame: 7 days from the beginning of each phase
Clinical Efficacy of Self-treatment of Acute HAE Attacks With s.c. Injections of Icatibant, Time to Symptom Relief Using VAS Score for a Single Primary Symptom by Patient Cohort
Subjects assessed angioedema attack symptoms using the visual analogue scale (VAS) for skin pain, skin swelling and abdominal pain. The VAS is a continuous scale comprised of a 100 mm in length line, anchored by 2 verbal descriptors, one for each symptom extreme 0 (no pain) and 100 (worst pain). The respondent is asked to place a mark on the VAS line (any where between 0 and 100 mm) at the point that represents their pain intensity. The score is determined by measuring the distance (mm) on the line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity. Score interpretation is: no pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm). Symptom relief is defined as at least a 50% reduction in a pre-dose VAS score of 30 mm or greater. The time to onset of symptom relief is defined as the first of 3 consecutive assessments at which symptom relief was observed.
Time frame: 48 hours post-dose
| Milestone | Naive Subjects/ Naive Treatment Phase | Non-Naive Subjects/ Self-administration Phase |
|---|---|---|
| Started | 25 | 79 |
| Completed | 19 | 0 |
| Not completed | 6 | 79 |
| Milestone | Naive Subjects/ Naive Treatment Phase | Non-Naive Subjects/ Self-administration Phase |
|---|---|---|
| Started | 19 | 78 |
| Completed | 19 | 77 |
| Not completed | 0 | 1 |
Clinical safety of self-treatment of acute HAE attacks with s.c. injections of icatibant was assessed by calculating the number of AEs occurred during the study. Only those adverse events occurring up to the earlier of 7 days from the start of the naive phase, study discontinuation and start of the self-administration phase are assessed. The Local Tolerability Assessment tool was used. Subjects and Investigators graded erythema/reddening, swelling, burning, pruritus/itching, warm sensation, and skin pain on a 0 to 3 severity scale.
| participants | Naive Subjects Administered Icatibant by Health Care Provider | Subjects Who Self-administered Icatibant (Naive) | Subjects Who Self-administered Icatibant (Non-naive) |
|---|---|---|---|
| Number of Participants With Adverse Events in Self-treatment of Acute HAE Attacks With s.c. Injections of Icatibant | 11 | 6 | 27 |
Subjects assessed angioedema attack symptoms using the visual analogue scale (VAS) for skin pain, skin swelling and abdominal pain. The VAS is a continuous scale comprised of a 100 mm in length line, anchored by 2 verbal descriptors, one for each symptom extreme 0 (no pain) and 100 (worst pain). The respondent is asked to place a mark on the VAS line (any where between 0 and 100 mm) at the point that represents their pain intensity. The score is determined by measuring the distance (mm) on the line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity. Score interpretation is: no pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm). Symptom relief is defined as at least a 50% reduction in a pre-dose VAS score of 30 mm or greater. The time to onset of symptom relief is defined as the first of 3 consecutive assessments at which symptom relief was observed.
| Hours | Naive Subjects Administered Icatibant by Health Care Provider | Subjects Who Self-administered Icatibant (Naive) | Subjects Who Self-administered Icatibant (Non-naive) |
|---|---|---|---|
| Clinical Efficacy of Self-treatment of Acute HAE Attacks With s.c. Injections of Icatibant, Time to Symptom Relief Using VAS Score for a Single Primary Symptom by Patient Cohort | 2.0 (1.0 to 4.2) | 3.1 (2.0 to 4.0) | 2.0 (1.0 to 5.3) |
Collected over 7 days from the beginning of each phase. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Naive Subjects Administered Icatibant by Health Care Provider | — | 0/22 (0%) | 7/22 (31.8%) |
| Subjects Who Self-administered Icatibant (Naive) | — | 0/19 (0%) | 6/19 (31.6%) |
| Subjects Who Self-administered Icatibant (Non-naive) | — | 0/78 (0%) | 21/78 (26.9%) |
| Event | Naive Subjects Administered Icatibant by Health Care Provider | Subjects Who Self-administered Icatibant (Naive) | Subjects Who Self-administered Icatibant (Non-naive) |
|---|---|---|---|
| Hereditary AngioedemaCongenital, familial and genetic disorders | 6/22 | 3/19 | 19/78 |
| HeadacheNervous system disorders | 1/22 | 1/19 | 2/78 |
| Blood pressure increasedInvestigations | 0/22 | 1/19 | 0/78 |
| Pharyngeal erythemaRespiratory, thoracic and mediastinal disorders | 0/22 | 1/19 | 0/78 |
| Feeling HotGeneral disorders | 0/22 | 1/19 | 0/78 |
| Local SwellingGeneral disorders | 0/22 | 1/19 | 0/78 |
| Edema PeripheralGeneral disorders | 0/22 | 1/19 | 0/78 |
| Localized edemaGeneral disorders | 0/22 | 1/19 | 0/78 |
| Skin LesionSkin and subcutaneous tissue disorders | 0/22 | 1/19 | 0/78 |
| Laryngeal edemaRespiratory, thoracic and mediastinal disorders | 0/22 | 1/19 | 0/78 |
| Age, Continuous(years) | Non-Naive Patients | Naive Patients | Total |
|---|---|---|---|
| Mean | 40.607 ± 13.044 | 44.68 ± 16.53 | 41.58 ± 13.98 |
| Sex: Female, Male(Participants) | Non-Naive Patients | Naive Patients | Total |
|---|---|---|---|
| Female | 52 | 16 | 68 |
| Male | 27 | 9 | 36 |
| Region of Enrollment(Participants) | Non-Naive Patients | Naive Patients | Total |
|---|---|---|---|
| France | 6 | 0 | 6 |
| Argentina | 18 | 5 | 23 |
| Spain | 9 | 2 | 11 |
| Denmark | 5 | 0 | 5 |
| Austria | 9 | 5 | 14 |
| Israel | 15 | 0 | 15 |
| Germany | 9 | 5 | 14 |
| Italy | 1 | 1 | 2 |
| Switzerland | 1 | 1 | 2 |
| United Kingdom | 6 | 6 | 12 |
Ran from Sep 2009 to primary completion in Jun 2011, 20 months.
Results were first posted in Jul 2014, 3 years 1 month after primary completion.
Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 20 months is close to that.
Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Icatibant